Effect of the nitric oxide donor V-PYRRO/NO on portal pressure and sinusoidal dynamics in normal and cirrhotic mice

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 294, Issue 6, 2008, Pages

  Edwards, Claire ^a   Feng, Hong Qiang ^b   Reynolds, Christopher ^a   Mao, Lan ^a   Rockey, Don C ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

In vivo microscopy; Liver; Portal hypertension; Sinusoidal flow; Sinusoidal resistance; Vasculature

Indexed keywords

CARBON TETRACHLORIDE; NITRIC OXIDE; NITRIC OXIDE DONOR; PYRROLIDINE DERIVATIVE; O(2) VINYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE; O(2)-VINYL-1-(PYRROLIDIN-1-YL)DIAZEN-1-IUM-1,2-DIOLATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; LIVER BLOOD FLOW; LIVER CIRRHOSIS; LIVER SINUSOID; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; VASODILATATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD FLOW VELOCITY; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; PATHOLOGY; REFERENCE VALUE;

ANIMALS; BLOOD FLOW VELOCITY; CARBON TETRACHLORIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED BALB C; NITRIC OXIDE DONORS; PORTAL PRESSURE; PYRROLIDINES; REFERENCE VALUES; VASODILATION;

EID: 48249121604     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00368.2007     Document Type: Article

References (27)

1. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 37: 902-908, 2003.
2. Baveja R, Kresge N, Ashburn JH, Keller S, Yokoyama Y, Sonin N, Zhang JX, Huynh T, Clemens MG. Potentiated hepatic microcirculatory response to endothelin-1 during polymicrobial sepsis. Shock 18: 415-422, 2002.
3. Clemens MG, Zhang JX. Regulation of sinusoidal perfusion: in vivo methodology and control by endothelins. Semin Liver Dis 19: 383-396, 1999.
4. Feron O, Michel JB, Sase K, Michel T. Dynamic regulation of endothelial nitric oxide synthase: complementary roles of dual acylation and caveolin interactions. Biochemistry 37: 193-200, 1998.
5. Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, Rodes J. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 346: 1056-1059, 1995.
6. Fiorucci S, Antonelli E, Morelli O, Mencarelli A, Casini A, Mello T, Palazzetti B, Tallet D, del Soldato P, Morelli A. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci USA 98: 8897-8902, 2001.
7. Fretland AJ, Omiecinski CJ. Epoxide hydrolases: biochemistry and molecular biology. Chem Biol Interact 129: 41-59, 2000.
8. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 299: 818-824, 2001.
9. Garcia-Cardena G, Martasek P, Masters BS, Skidd PM, Couet J, Li S, Lisanti MP, Sessa WC. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the NOS caveolin binding domain in vivo. J Biol Chem 272: 25437-25440, 1997.
10. 2-vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (V-PYRRO/NO) protects HepG2 cells against cytochrome P450 2E1-dependent toxicity. Mol Pharmacol 65: 130-138, 2004.
11. Gross JF, Aroesty J. Mathematical models of capillary flow: a critical review. Biorheology 9: 225-264, 1972.
12. Kochanek KD, Smith BL. Death: preliminary data for 2002. Natl Vital Stat Rep 52: 1-48, 2004.
13. Liu J, Li C, Waalkes MP, Clark J, Myers P, Saavedra JE, Keefer LK. The nitric oxide donor, V-PYRRO/NO, protects against acetaminophen-induced hepatotoxicity in mice. Hepatology 37: 324-333, 2003.
14. Liu S, Premont RT, Kontos CD, Zhu S, Rockey DC. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med 11: 952-958, 2005.
15. Luo Z, Fujio Y, Kureishi Y, Rudic RD, Daumerie G, Fulton D, Sessa WC, Walsh K. Acute modulation of endothelial Akt/PKB activity alters nitric oxide-dependent vasomotor activity in vivo. J Clin Invest 106: 493-499, 2000.
16. Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 339: 533-541, 1998.
17. Moal F, Veal N, Vuillemin E, Barriere E, Wang J, Fizanne L, Oberti F, Douay O, Gallois Y, Bonnefont-Rousselot D, Rousselet MC, Cales P. Hemodynamic and antifibrotic effects of a selective liver nitric oxide donor V-PYRRO/NO in bile duct ligated rats. World J Gastroenterol 12: 6639-6645, 2006.
18. Morillas RM, Planas R, Cabre E, Galan A, Quer JC, Feu F, Garcia Pagan JC, Bosch J, Gassull MA. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects. Hepatology 20: 1502-1508, 1994.
19. Ricciardi R, Foley DP, Quarfordt SH, Saavedra JE, Keefer LK, Wheeler SM, Donohue SE, Callery MP, Meyers WC. V-PYRRO/NO: an hepatoselective nitric oxide donor improves porcine liver hemodynamics and function after ischemia reperfusion. Transplantation 71: 193-198, 2001.
20. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 114: 344-351, 1998.
21. Rodriguez-Vilarrupla A, Fernandez M, Bosch J, Garcia-Pagan JC. Current concepts on the pathophysiology of portal hypertension. Ann Hepatol 6: 28-36, 2007.
22. Saavedra JE, Billiar TR, Williams DL, Kim YM, Watkins SC, Keefer LK. Targeting nitric oxide (NO) delivery in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor-α- induced apoptosis and toxicity in the liver. J Med Chem 40: 1947-1954, 1997.
23. Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, Sessa WC, Groszmann RJ. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 117: 1222-1228, 1999.
24. Stinson SF, House T, Bramhall C, Saavedra JE, Keefer LK, Nims RW. Plasma pharmacokinetics of a liver-selective nitric oxide-donating diazeniumdiolate in the male C57BL/6 mouse. Xenobiotica 32: 339-347, 2002.
25. Van de Casteele M, Hosli M, Sagesser H, Reichen J. Intraportal administration of glyceryl trinitrate or nitroprusside exerts more systemic than intrahepatic effects in anaesthetised cirrhotic rats. J Hepatol 31: 300-305, 1999.
26. Vorobioff J, Bredfeldt JE, Groszmann RJ. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 87: 1120-1126, 1984.
27. Zimmerhackl B, Parekh N, Brinkhus H, Steinhausen M. The use of fluorescent labeled erythrocytes for intravital investigation of flow and local hematocrit in glomerular capillaries in the rat. Int J Microcirc Clin Exp 2: 119-129, 1983.